文献速递病毒性肝炎艾滋病与性传播感染

当前阿片受体激动剂治疗对吸毒人群丙型肝炎治疗启动的影响:DAA时代基于人群的研究

The Impact of Current Opioid Agonist Therapy on Hepatitis C Virus Treatment Initiation Among People Who Use Drugs From the Direct-acting Antiviral (DAA) Era: A Population-Based Study.
PubMed 文献 · Clin Infect Dis · 2022-01-01

该研究利用不列颠哥伦比亚省丙型肝炎检测者队列(1992–2019年链接行政数据),纳入13 803名有注射吸毒或阿片使用障碍的慢性HCV感染者,评估当前OAT与HCV治疗启动的关联。结果显示,当前OAT者中47%(2704/5770)启动HCV治疗,非当前OAT者中22%(1778/8033)启动;时间事件分析中当前OAT与更高的HCV治疗启动可能性相关(调整风险比1.84,95%CI 1.50–2.26)。结论认为当前OAT与更高治疗启动可能性相关,但许多接受OAT的PWUD尚未接受HCV治疗,需加强物质使用照护与HCV治疗的整合。

要点

  • 当前OAT与慢性HCV的PWUD启动HCV治疗的可能性更高相关(aHR 1.84,95%CI 1.50–2.26)。
  • 当前OAT者HCV治疗启动比例为47%,非当前OAT者为22%。
  • 许多接受OAT的PWUD仍未启动HCV治疗,需加强服务整合。

核心结论

  • 当前OAT与PWUD启动HCV治疗的可能性更高相关,但许多接受OAT的PWUD尚未接受HCV治疗。
  • 需要加强物质使用照护与HCV治疗之间的整合以改善PWUD整体健康。

研究设计与样本

  • 基于不列颠哥伦比亚省丙型肝炎检测者队列的人群水平链接行政数据集,链接1992年至2019年的医疗就诊、住院、实验室、处方药和死亡数据。
  • 纳入有注射吸毒或阿片使用障碍且患慢性HCV感染的PWUD,共13 803人。
  • 主要结局为HCV治疗启动,采用次分布比例风险模型评估与当前OAT的关系。

主要发现

  • 研究期末当前接受OAT者中47%(2704/5770)已启动HCV治疗,非当前OAT者中22%(1778/8033)已启动HCV治疗。
  • 在慢性HCV感染的PWUD中,时间事件分析显示当前OAT与更高的HCV治疗启动可能性相关(调整风险比1.84,95%CI 1.50–2.26)。

临床怎么用

  • 对接受OAT的PWUD应主动评估并促进HCV治疗启动,将物质使用照护与HCV治疗服务整合。
  • 当前OAT状态可作为识别HCV治疗启动机会的临床标志,但仍需关注未启动治疗者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence that opioid agonist therapy (OAT) is associated with increased odds of hepatitis C virus (HCV) treatment initiation among people who use drugs (PWUD) is emerging. The objective of this study was to determine the association between current OAT and HCV treatment initiation among PWUD in a population-level linked administrative dataset. METHODS: The British Columbia Hepatitis Testers Cohort was used for this study, which includes all people tested for or diagnosed with HCV in British Columbia, linked to medical visits, hospitalizations, laboratory, prescription drug, and mortality data from 1992 until 2019. PWUD with injecting drug use or opioid use disorder and chronic HCV infection were identified for inclusion in this study. HCV treatment initiation was the main outcome, and subdistribution proportional hazards modeling was used to assess the relationship with current OAT. RESULTS: In total, 13 803 PWUD with chronic HCV were included in this study. Among those currently on OAT at the end of the study period, 47% (2704/5770) had started HCV treatment, whereas 22% (1778/8033) of those not currently on OAT had started HCV treatment. Among PWUD with chronic HCV infection, current OAT was associated with higher likelihood of HCV treatment initiation in time to event analysis (adjusted hazard ratio 1.84 [95% confidence interval {CI}, 1.50, 2.26]). CONCLUSIONS: Current OAT was associated with a higher likelihood of HCV treatment initiation. However, many PWUD with HCV currently receiving OAT have yet to receive HCV treatment. Enhanced integration between substance use care and HCV treatment is needed to improve the overall health of PWUD.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Bartlett SR, Wong S, Yu A, et al. The Impact of Current Opioid Agonist Therapy on Hepatitis C Virus Treatment Initiation Among People Who Use Drugs From the Direct-acting Antiviral (DAA) Era: A Population-Based Study. Clin Infect Dis. 2022. PMID: 34125883. doi:10.1093/cid/ciab546

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。